Subcutaneous Pentylenetetrazole

A ter el at. (1984) documented the anticonvulsant properties of PBO and compared them with those of clinically established anti epileptic drugs. PBO administered inlrapcritoncally to mice exerted peak anti maximal electroshock activity and peak neurotoxicity at 5 and 7 hours, respectively. The median neuroluxic dose was I.69U mg kg"1. In the maximal electroshock seizure test I he median effective dose (HD j) was 457 mg kg"1 and the protective index (PI) was 3,69. In the subcutaneous pentylenetetrazol (PTZ) test the ED u was 443 mg kg 1 and PI was 3.81. PBO prevented seizure spread and elevated seizure threshold, and its PI compared favourably with those of clinically useful anticonvulsants,... 

A number of animal models are currently available for anticonvulsant screening [13,14]. Two basic models used are Maximal Electroshock Test (MEST) and Subcutaneous Pentylenetetrazole Seizure Threshold Test (ScMET). Anticonvulsant activity in MEST predicts the ability of the testing material or compound in preventing the spread of seizure discharge and effectiveness in the treatment of grandmal seizures, while activity in ScMET predicts the ability to elevate seizure threshold and effectiveness in myoclonic seizures. 

Copper complexes listed in Table 6.22 have been reported [324-327] to have anticonvulsant activity in the /rmol/kg dose range following subcutaneous or intraperitoneal administration to rodent models of grand mal or petit mal seizures, maximal electroshock- or pentylenetetrazol-induced seizures [328, 329]. Some of these compounds had a rapid onset of action, within 30 min following administration, and the anticonvulsant effect persisted for up to 8 h. Others had a delayed onset of action, approximately 4 h, with a prolonged effect lasting for up to 24 h. Most of these complexes were found to be more effective in the pentylenetetrazol-induced seizure model, but lipophilic complexes were found to be effective in both models of seizure. 

---